

MEETING ABSTRACT

Open Access

The use of amisulpride in schizophrenic patients with resistant symptomatology

Dimitrios Kalfas*, Sophia Markou, Apostolos Gkletsos, Maria Parga, Theodoros Karras

From 1st International Congress on Neurobiology and Clinical Psychopharmacology and European Psychiatric Association Conference on Treatment Guidance
Thessaloniki, Greece. 19-22 November 2009

Background

The purpose of this study was to evaluate the use of the pharmaceutical drug Amisulpride (Solian) in schizophrenic patients with resistant semiology

Materials and methods

The material of this study was 21 patients (17 men and 4 women) who were diagnosed with schizophrenic disorder paranoid type based on DSM-IV, and were recorded with durable symptomatology (delusions, paranoid ideas etc.) even though the continuous issuing of Amisulpride in normal doses (800-1200 mg/daily). In these patients was given Amisulpride in larger doses than the proposed (1600-2000 mg/daily). The evaluation was done with the PANSS scale

Results

After a 30 day time interval and while the continuous issuing of Amisulpride in larger doses was observed considerably reprocess of the resistant symptoms, fact that recorded at the grade alleviation at PANSS scale

Conclusions

Is concluding that the continuous issuing of Amisulpride in larger doses than the normal ones help considerably in obliteration of the durable symptoms of schizophrenia.

Published: 22 April 2010

doi:10.1186/1744-859X-9-S1-S135

Cite this article as: Kalfas et al.: The use of amisulpride in schizophrenic patients with resistant symptomatology. *Annals of General Psychiatry* 2010 **9**(Suppl 1):S135.

Psychiatric Clinic, Giannitsa General Hospital, 58100 Giannitsa, Greece

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

